In this new article, Matthew Mollan, Ph.D., CEO of Experic, explores the forces reshaping pharmaceutical manufacturing, from geopolitical pressures and regulatory changes to supply chain risks and the rapid surge in U.S. investment. As highlighted in the article, more than $158 billion has already been committed to domestic manufacturing, intensifying the race to secure the right partners.
For innovators, the challenge isn’t just deciding to onshore, it’s finding a partner with the expertise, flexibility, and available capacity to execute.
In this article, you’ll learn:
- What’s driving the shift toward U.S.-based manufacturing
- The key challenges in securing specialty capacity
- How to evaluate the right CDMO partner for your program
- Why acting early can create a competitive advantage
Fill out the form below to access the full article and gain insights to help you navigate this rapidly evolving landscape.